Pmu72 - Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the Fda, 2015-2016

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1908
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Drug Development Process and Novel Drugs Approved by FDA for 2017 -18

Applied Clinical Research, Clinical Trials and Regulatory Affairs
2018English

Characteristics of Pivotal Trials and FDA Review of Innovative Devices

PLoS ONE
Multidisciplinary
2015English

Summaries of Safety Labeling Changes Approved by FDA--boxed Warnings Highlights March-June 2016

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2016English

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2014English

S18 Longitudinal Assessment of Biomarkers for Clinical Trials of Novel Therapeutic Agents: The Run-In Study

Thorax
PulmonaryRespiratory Medicine
2010English

From the FDA: Heart Pump Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

From the FDA: Epilepsy Drug Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

From the FDA: Testosterone Patch Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1995English

From the FDA: Chickenpox Vaccine Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1995English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy